1 Hacke W，Kaste M，Fieschi C，et al. Intravenous

thrombolysis with recombinant tissue plasminogen

activator for acute hemispheric stroke. The European

Cooperative Acute Stroke Study (ECASS)[J]. JAMA，

1995，274：1017-1025.

2 The National Institute of Neurological Disorders and

Stroke rt-PA Stroke Study Group. Tissue plasminogen

activator for acute ischemic stroke[J]. N Engl J Med，

1995，333：1581-1587.

3 Lees KR，Bluhmki E，von Kummer R，et al. Time

to treatment with intravenous alteplase and outcome

in stroke：an updated pooled analysis of ECASS，

ATLANTIS，NINDS，and EPITHET trials[J]. Lancet，

2010，375：1695-1703.

4 Tung CE，Win SS，Lansberg MG. Cost-effectiveness

of tissue-type plasminogen activator in the 3- to

4.5- hour time window for acute ischemic stroke[J].

Stroke，2011，42：2257-2262.

5 国家统计局. 2010年中国人口普查[EB/OL].[2015-10-

15]. 网址：http：//www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/

indexch.htm.

6 国家卫生部. 2012年中国卫生统计年鉴[M]. 北京：北

京协和出版社，2012.

7 Wang YL，Pan YS，Zhao XQ，et al. Recurrent stroke

was associated with poor quality of life in patients

with transient ischemic attack or minor stroke：finding

from the CHANCE trial[J]. CNS Neurosci Ther，2014，

20：1029-1035.

8 《中国药物经济学评价指南》课题组；刘国恩，胡善

联，吴久鸿. 中国药物经济学评价指南(2011版)[J]. 中

国药物经济学，2011，3：6-48.

9 Yang G，Wang Y，Zeng Y，et al. Rapid health

transition in China，1990-2010：findings from the

Global Burden of Disease Study 2010[J]. Lancet，

2013，381：1987-2015.

10 Wang Y，Liao X，Zhao X，et al. Using recombinant

tissue plasminogen activator to treat acute ischemic

stroke in China：analysis of the results from the

Chinese National Stroke Registry (CNSR)[J]. Stroke，

2011，42：1658-1664.

11 Fagan SC，Morgenstern LB，Petitta A，et al. Costeffectiveness

of tissue plasminogen activator for acute

ischemic stroke[J]. NINDS rt-PA Stroke Study Group.

Neurology，1998，50：883-890.

12 Sinclair SE，Frighetto L，Loewen PS，et al. Costutility

analysis of tissue plasminogen activator therapy

for acute ischaemic stroke：a Canadian healthcare

perspective[J]. Pharmacoeconomics，2001，19：927-

936.

13 Sandercock P，Berge E，Dennis M，et al. Costeffectiveness

of thrombolysis with recombinant tissue

plasminogen activator for acute ischemic stroke

assessed by a model based on UK NHS costs[J].

Stroke，2004，35：1490-1497.

14 Ehlers L，Andersen G，Clausen LB，et al. Costeffectiveness

of intravenous thrombolysis with

alteplase within a 3-hour window after acute ischemic

stroke[J]. Stroke，2007，38：85-89.

15 Jung KT，Shin DW，Lee KJ，et al. Cost-effectiveness

of recombinant tissue plasminogen activator in the

management of acute ischemic stroke：a systematic

review[J]. J Clin Neurol，2010，6：117-126.

16 Kim AS，Nguyen-Huynh M，Johnston SC. A costutility

analysis of mechanical thrombectomy as

an adjunct to intravenous tissue-type plasminogen

activator for acute large-vessel ischemic stroke[J].

Stroke，2011，42：2013-2018.

17 Pan Y，Chen Q，Zhao X，et al. Cost-effectiveness

of thrombolysis within 4.5 hours of acute ischemic

stroke in China[J]. PLoS ONE，2014，9:e110525.